Home>Topics>Stocks>Alexion Pharmaceuticals

Alexion Pharmaceuticals ALXN

  1. All
  2. Commentary
  3. Headlines
    1. End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies

      Headlines

      Mon, 20 Oct 2014

      chance, to drive these companies stock prices considerably through the rest of the year and beyond. Alexion Pharmaceuticals (NASDAQ: ALXN ) Alexion is a biopharmaceutical company that discovers, develops and commercializes medicines for

    2. Alexion submits NDA in Japan for asfotase alfa

      Headlines

      Wed, 15 Oct 2014

      Alexion Pharmaceuticals (NASDAQ: ALXN ) submits a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for asfotase alfa , an enzyme replacement

    3. Alexion to report on October 23

      Headlines

      Thu, 9 Oct 2014

      Alexion Pharmaceuticals ( ALXN -1.2% ) will report Q3 results on October 23 before the open. The conference call will begin at 10:00 am ET. Consensus view is EPS of $1.16 on revenues of $542M. Post your comment!

    4. Alexion names new chairman

      Headlines

      Thu, 9 Oct 2014

      Alexion Pharmaceuticals (NASDAQ: ALXN ) appoints Leonard Bell, M.D., Chairman of the Board replacing the recently-deceased Max Link, Ph.D. Dr. Bell is the principal founder of the company. Post your comment!

    5. Alexion Chairman passes suddenly

      Headlines

      Tue, 7 Oct 2014

      Alexion Pharmaceuticals ( ALXN -3.3% ) Chairman Max Link, Ph.D., died unexpectedly on October 5 while on a business trip. He was 74 years old. The BOD will announce a new chairman shortly. Post your comment!

    6. Encouraging Phase 2 results for Alexion's asfotase alfa

      Headlines

      Fri, 19 Sep 2014

      Alexion Phharmaceuticals (NASDAQ: ALXN ) presented data from two Phase 2 studies of asfotase alfa earlier today at the European Society for Pediatric Endocrinology Meeting

    7. Execs move up at Alexion

      Headlines

      Wed, 17 Sep 2014

      Alexion Pharmaceuticals (NASDAQ: ALXN ) promotes key executives. EVP and Chief Commercial Officer David Hallal promoted to COO. SVP and Chief HR Officer Clare Carmichael

    8. Is Intercept Pharmaceuticals Building The Next Great Specialty Franchise?

      Headlines

      Mon, 15 Sep 2014

      By Stephen Simpson, CFA : As great as Alexion (NASDAQ: ALXN ) has shown itself to be with its orphan drug Soliris for rare kidney ailments, Intercept Pharmaceuticals (NASDAQ: ICPT ) may

    9. Japanese regulators tag asfotase alfa an orphan drug for rare bone disorder

      Headlines

      Mon, 8 Sep 2014

      The Japanese Ministry of Health, Labour and Welfare (MHLW) designates Alexion Pharmaceuticals ' (NASDAQ: ALXN ) asfotase alfa an Orphan Drug for the treatment of patients with hypophosphatasis (HPP), an ultra-rare metabolic disease

    10. From Barron’s, August 11, 2014 (Part 1)

      Commentary

      Sat, 9 Aug 2014

      politicians. But that alone won’t stop inversions and possible future candidates with 45% or more revenues from overseas include ALXN , IPG, JCI, OI, MON . For the week , Dow +0.37% , SP500 +0.33% , Nasdaq Comp +0.42% , Russell 2000 +1.48

    « Prev12345Next »
    Content Partners